Treatment of basal cell carcinoma: is intralesional methotrexate an option?

Kamran BalighiAutoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran; ;Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

Mahshid Sadat AnsariDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

http://orcid.org/0000-0001-8586-2432

Mehdi MirzaiepourDepartment of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

Maryam DaneshpazhoohAutoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran; ;Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran

HamidReza MahmoudiAutoimmune Bullous Diseases Research Center, Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran; ;Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, IranCorrespondence[email protected]

References

Berking C, Hauschild A, Kölbl O, et al. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014;111:389.
PubMed Web of Science ®Google Scholar
Alter M, Hillen U, Leiter U, et al. Current diagnosis and treatment of basal cell carcinoma. J Dtsch Dermatol Ges. 2015;13:863–875.
PubMed Web of Science ®Google Scholar
Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63:689–702.
PubMed Web of Science ®Google Scholar
Pfeiffer P, Hansen O, Rose C. Systemic cytotoxic therapy of basal cell carcinoma: a review of the literature. Eur J Cancer Clin Oncol. 1990;26:73–77.
Google Scholar
Van Scott E, Shaw R, Crounse R, et al. Effects of methotrexate on basal-cell carcinomas. Arch Dermatol. 1960;82:762–771.
PubMedGoogle Scholar
Klein E, Stoll H, Milgrom H, et al. Tumors of the skin. iv. double-blind study on effects of local administration of anti-tumor agents in basal cell carcinoma. J Investig Dermatol. 1965;44:351.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Treatment of basal cell carcinoma: is intralesional methotrexate an option?

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Treatment of basal cell carcinoma: is intralesional methotrexate an option?

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date